Connie Li, NP
Nurse Practitioner · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 4
- Since medical school
- 12 years
- Graduated 2014
Offices
4 locations · UCSF Medical Group Business Services · University of California San Francisco
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Connie Li’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$35,045
Medicare paid this office $35,045 for 136 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 112 | $19,341 | $100 |
| Return visit (30+ min) | 33 | $2,930 | $73 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 77 | $1,249 | $11 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $842 | $70 |
Who their Medicare patients are
136 Original Medicare patients in 2024. Average age 73 · Women 49% · Also on Medicaid 17% · Health risk score 2.40. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 60% · Cancer 51% · Diabetes 28% · Chronic kidney disease 19% · Coronary heart disease 18% · Depression 14% · Atrial fibrillation 13% · COPD 10% · Heart failure 9%.
The office billed $298,022, Medicare allowed $46,320 and paid $35,045; for 628 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 136 | 628 | 73 | 2.40 | $298,022 | $35,045 |
| 2023 | 97 | 202 | 74 | 2.19 | $135,112 | $18,891 |
| 2022 | 104 | 161 | 74 | 2.76 | $95,641 | $14,325 |
| 2021 | 67 | 121 | 74 | 2.34 | $50,211 | $9,743 |
| 2020 | 98 | 206 | 72 | 2.84 | $49,725 | $12,158 |
| 2019 | 81 | 126 | 74 | 2.59 | $12,877 | $7,691 |
| 2018 | 40 | 44 | 76 | 2.79 | $4,166 | $2,331 |
| 2017 | 12 | 12 | 68 | 1.72 | $1,283 | $769 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 89 | $16,507 | $104 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $994 | $62 |
2022: 2 services
| Long return visit (40+ min) | 59 | $8,832 | $109 |
| Return visit (30+ min) | 45 | $4,975 | $69 |
2021: 1 service
| Return visit (30+ min) | 61 | $8,478 | $79 |
2020: 2 services
| Return visit (30+ min) | 93 | $10,646 | $59 |
| Return visit (30+ min) | 13 | $1,069 | $59 |
2019: 2 services
| Return visit (30+ min) | 74 | $6,661 | $59 |
| Long return visit (40+ min) | 13 | $1,030 | $79 |
2018: 1 service
| Return visit (30+ min) | 38 | $2,161 | $51 |
Drugs they prescribed that Part D paid
$73,101
Pharmacies billed $73,101 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
49 generic and fewer than 11 brand-name prescriptions · $73,101 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 72 | 33 | None | None | $73,101 |
| 2023 | 68 | 33 | None | None | $109,568 |
| 2022 | 366 | 108 | 6% (21) | 54% | $2,813,744 |
| 2021 | 408 | 123 | 6% (25) | 39% | $1,832,098 |
| 2020 | 870 | 166 | 8% (71) | 29% | $2,435,389 |
| 2019 | 630 | 147 | 9% (58) | 17% | $418,907 |
| 2018 | 390 | 113 | 17% (66) | 11% | $84,231 |
| 2017 | 200 | 64 | 19% (37) | None | $11,095 |
| 2016 | 636 | 156 | 73% (466) | 11% | $51,505 |
| 2015 | 621 | 128 | 73% (455) | 10% | $51,848 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 8 drugs
| Tagrisso | 104 | $1,992,024 | $19,154 |
| Alecensa | 24 | $426,509 | $17,771 |
| Eliquis | 17 | $10,367 | $610 |
| Oxycodone | 13 | $321 | $25 |
| Gabapentin | 17 | $225 | $13 |
| Levothyroxine | 11 | $170 | $15 |
| Dexamethasone | 11 | $160 | $15 |
| Prednisone | 17 | $96 | $6 |
2021: 14 drugs
| Tagrisso | 68 | $1,242,741 | $18,276 |
| Mekinist | 11 | $148,311 | $13,483 |
| Tafinlar | 11 | $136,601 | $12,418 |
| Iressa | 11 | $89,368 | $8,124 |
| Eliquis | 20 | $10,808 | $540 |
| Mirtazapine | 13 | $694 | $53 |
| Ondansetron | 21 | $505 | $24 |
| Levothyroxine | 13 | $439 | $34 |
| Gabapentin | 30 | $428 | $14 |
| Prochlorperazine Maleate | 19 | $254 | $13 |
| Oxycodone | 14 | $240 | $17 |
| Omeprazole | 11 | $218 | $20 |
| Dexamethasone | 12 | $208 | $17 |
| Pantoprazole | 11 | $153 | $14 |
2020: 22 drugs
| Tagrisso | 92 | $1,429,299 | $15,536 |
| Lorbrena | 11 | $178,813 | $16,256 |
| Mekinist | 11 | $139,639 | $12,694 |
| Erlotinib | 29 | $129,872 | $4,478 |
| Tafinlar | 11 | $123,161 | $11,196 |
| Eliquis | 38 | $19,860 | $523 |
| Vemlidy | 16 | $19,423 | $1,214 |
| Dexamethasone | 53 | $818 | $15 |
| Albuterol Sulfate Hfa | 13 | $622 | $48 |
| Prochlorperazine Maleate | 39 | $507 | $13 |
| Mirtazapine | 35 | $492 | $14 |
| Ondansetron | 43 | $474 | $11 |
| Hydrocodone-Acetaminophen | 23 | $468 | $20 |
| Levothyroxine | 26 | $449 | $17 |
| Gabapentin | 60 | $410 | $7 |
| Omeprazole | 28 | $371 | $13 |
| Potassium Chloride | 15 | $369 | $25 |
| Oxycodone | 21 | $366 | $17 |
| Morphine Sulfate Er | 12 | $218 | $18 |
| Prednisone | 35 | $169 | $5 |
| Pantoprazole | 15 | $156 | $10 |
| Amlodipine Besylate | 20 | $55 | $3 |
2019: 17 drugs
| Lorbrena | 11 | $131,742 | $11,977 |
| Erlotinib | 11 | $77,031 | $7,003 |
| Xarelto | 24 | $13,111 | $546 |
| Oxycontin | 11 | $3,209 | $292 |
| Tenofovir Disoproxil | 11 | $1,604 | $146 |
| Gabapentin | 49 | $818 | $17 |
| Ondansetron | 58 | $783 | $13 |
| Dexamethasone | 31 | $629 | $20 |
| Potassium Chloride | 19 | $548 | $29 |
| Mirtazapine | 31 | $517 | $17 |
| Prochlorperazine Maleate | 47 | $404 | $9 |
| Omeprazole | 41 | $318 | $8 |
| Oxycodone | 18 | $307 | $17 |
| Hydrocodone-Acetaminophen | 16 | $232 | $14 |
| Lorazepam | 17 | $132 | $8 |
| Amlodipine Besylate | 13 | $124 | $10 |
| Prednisone | 17 | $105 | $6 |
2018: 8 drugs
| Mirtazapine | 24 | $416 | $17 |
| Dexamethasone | 33 | $400 | $12 |
| Oxycodone | 20 | $321 | $16 |
| Gabapentin | 20 | $294 | $15 |
| Ondansetron | 27 | $256 | $9 |
| Prochlorperazine Maleate | 21 | $108 | $5 |
| Lorazepam | 25 | $100 | $4 |
| Amlodipine Besylate | 15 | $78 | $5 |
2017: 6 drugs
| Oxycodone | 12 | $408 | $34 |
| Mirtazapine | 16 | $238 | $15 |
| Dexamethasone | 19 | $204 | $11 |
| Hydrocodone-Acetaminophen | 13 | $101 | $8 |
| Prochlorperazine Maleate | 15 | $65 | $4 |
| Lorazepam | 11 | $34 | $3 |
2016: 15 drugs
| Oxycontin | 34 | $17,617 | $518 |
| Oxycodone-Acetaminophen | 75 | $5,525 | $74 |
| Hydrocodone-Acetaminophen | 166 | $5,523 | $33 |
| Lyrica | 12 | $5,157 | $430 |
| Fentanyl | 35 | $3,669 | $105 |
| Morphine Sulfate Er | 50 | $2,036 | $41 |
| Oxycodone | 49 | $1,539 | $31 |
| Gabapentin | 30 | $1,385 | $46 |
| Methadone | 12 | $419 | $35 |
| Zolpidem | 18 | $254 | $14 |
| Hydromorphone | 18 | $246 | $14 |
| Baclofen | 12 | $197 | $16 |
| Tizanidine | 12 | $127 | $11 |
| Tramadol | 13 | $71 | $5 |
| Trazodone | 11 | $43 | $4 |
2015: 14 drugs
| Oxycontin | 30 | $16,782 | $559 |
| Hydrocodone-Acetaminophen | 185 | $6,819 | $37 |
| Morphine Sulfate Er | 48 | $5,246 | $109 |
| Lyrica | 13 | $4,773 | $367 |
| Oxycodone-Acetaminophen | 60 | $4,580 | $76 |
| Fentanyl | 36 | $3,075 | $85 |
| Oxycodone | 52 | $1,719 | $33 |
| Tizanidine | 16 | $859 | $54 |
| Gabapentin | 33 | $852 | $26 |
| Methadone | 11 | $580 | $53 |
| Hydromorphone | 17 | $283 | $17 |
| Zolpidem | 14 | $114 | $8 |
| Carisoprodol | 12 | $82 | $7 |
| Trazodone | 12 | $44 | $4 |
Money from drug and device companies
$155 in 2025
| 2025 | 2 | 2 | None | $155 |
| 2023 | 1 | 1 | None | $102 |
| 2022 | 1 | 1 | None | $18 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $125 | 1 payment
|
| Novartis Pharmaceuticals | Scemblix | $31 | 1 payment
|
See all 2 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-27 | Fruzaqla | $125 |
| Novartis Pharmaceuticals | Meals · 2025-02-15 | Scemblix | $31 |
See earlier years (2023, 2022)
2023: $102
| BeiGene USA | Brukinsa | $102 | 1 payment
|
2022: $18
| Pfizer | Lorbrena | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1528464476
- Licence
- CA 95001530
- Group
- UCSF Medical Group Business Services · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 875 Blake Wilbur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2014-11-05
- NPI last updated
- 2019-11-27
This is when the NPI record was last certified, not a medical board exam.